Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer

In brief

The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants. In addition, researchers will assess data about preliminary efficacy in patients with this treatment approach.

Key facts

Study ID

NCT00320749

Run by

Tony Bekaii-Saab

People needed

21

Starts

2005-12-01

Expected to finish

2011-01-01

Last updated by the study team

2016-06-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adenocarcinoma of the pancreas
• no prior chemo except adjuvant
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• peripheral neuropathy </= Gr. 1

You may not qualify if…

• Pregnant/lactating females
• Uncontrolled heart disease, diabetes, psychiatric disorder
• Therapeutic doses of Warfarin

Where it is running

• The University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.